•Enrolled residents
of nursing or residential homes in four
•areas (2001-2004);
followed patients to April 2006
•
•All patients had
been diagnosed with possible or
•probable
Alzheimer’s and all had taken APs
for
•≥ 3
months (APs = risperidone, thioridazine,
haloperidol,
•trifluoperazine, or chlorpromazine)
•
•Mean duration of
drug use: 25 months
•